This site is intended for healthcare professionals
Drug news

RELEVANCE phase III trial of Revlimid fails to meet endpoint in follicular lymphoma.- Celgene Corp.

Read time: 1 mins
Last updated:29th Jun 2018
Published:4th Jun 2018
Source: Pharmawand

Celgene Corporation announced additional results from RELEVANCE, a phase III, randomized, open-label, international clinical study of Revlimid (lenalidomide) plus rituximab (R2), followed by R2 maintenance, an investigational regimen, compared to the standard of care treatment of rituximab plus chemotherapy (R-chemo: R-CHOP, R-bendamustine or R-CVP) followed by rituximab maintenance in patients with previously untreated follicular lymphoma. Investigators found that treatment with a chemotherapy-free R2 regimen offered numerically similar efficacy results for the primary endpoints of progression free survival (PFS) and complete response or unconfirmed complete response (CR/CRu) at 120 weeks with a different safety profile than treatment with the conventional R-chemo standard. As previously disclosed, the study did not achieve the primary endpoints of superior PFS and CR/CRu.

The co-primary efficacy endpoints of the study were CR and CRu at 120 weeks and PFS during the pre-planned analysis (final analysis of CR/CRu and interim analysis of PFS). An analysis of the findings found that 48% of patients in the R2 arm and 53% of those receiving R-chemo maintained CR/Cru 120 weeks after randomization, with a 3-year estimated interim PFS rate of 77% and 78% respectively. Preliminary overall survival, one of the study’s secondary endpoints, showed a 3-year survival rate of 94% in both treatment arms.

Other secondary endpoints included number of patients with adverse events, time to treatment failure, event-free survival, time to next anti-lymphoma treatment, time to next chemotherapy treatment, overall response rate at 120 weeks based on International Working Group (IWG) 1999 criteria, and health-related quality of life as measured by the EORTC QLQ-C30. The majority of patients in both arms completed treatment (69% R2 and 71% R-chemo). The most common Grade 3/4 TEAEs in both arms were neutropenia (32% R2 vs. 50% R-chemo), febrile neutropenia (2% R2 vs. 7% R-chemo) and cutaneous events (7% R2 vs. 1% R-chemo). Data were presented at the 54th Annual American Society of Clinical Oncology Scientific Sessions (ASCO).

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.